(19)
(11) EP 4 448 802 A1

(12)

(43) Date of publication:
23.10.2024 Bulletin 2024/43

(21) Application number: 22834561.7

(22) Date of filing: 08.12.2022
(51) International Patent Classification (IPC): 
C12Q 1/70(2006.01)
A61K 39/12(2006.01)
A61K 39/00(2006.01)
C07K 14/005(2006.01)
(52) Cooperative Patent Classification (CPC):
C12Q 1/701; C12Q 2600/106; A61K 39/12; C07K 14/005; C12N 2760/18334; C12N 2760/18322
(86) International application number:
PCT/EP2022/084976
(87) International publication number:
WO 2023/110618 (22.06.2023 Gazette 2023/25)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 16.12.2021 EP 21215259

(71) Applicant: Janssen Vaccines & Prevention B.V.
2333 CN Leiden (NL)

(72) Inventors:
  • LANGEDIJK, Johannes, Petrus, Maria
    2333 CN Leiden (NL)
  • BAKKERS, Mark, Johannes, Gerardus
    2333 CN Leiden (NL)
  • RITSCHEL, Tina
    2333 CN Leiden (NL)
  • JURASZEK, Jaroslaw
    2333 CN Leiden (NL)

(74) Representative: Beslier, Victor et al
Janssen Vaccines & Prevention B.V. Archimedesweg 4-6
2333 CN Leiden
2333 CN Leiden (NL)

   


(54) STABILIZED PRE-FUSION HMPV FUSION PROTEINS